Carotuximab: Difference between revisions

Latest revision as of 19:25, 22 March 2025

A monoclonal antibody used in cancer treatment

Carotuximab is a monoclonal antibody that has been investigated for its potential use in the treatment of various types of cancer. It is designed to target specific proteins on the surface of cancer cells, thereby inhibiting their growth and proliferation.

Mechanism of Action[edit]

Carotuximab functions by binding to a specific antigen present on the surface of certain cancer cells. This binding can block the signaling pathways that promote tumor growth and survival. Additionally, carotuximab may recruit components of the immune system to attack and destroy the cancer cells.

Clinical Applications[edit]

Carotuximab has been studied in clinical trials for its efficacy in treating several types of cancer, including:

In these studies, carotuximab has been evaluated both as a monotherapy and in combination with other chemotherapeutic agents.

Development and Research[edit]

The development of carotuximab involves extensive preclinical and clinical trials to assess its safety, efficacy, and optimal dosing regimens. Research is ongoing to determine the full potential of carotuximab in cancer therapy, including its use in combination with other targeted therapies and immunotherapies.

Side Effects[edit]

As with many monoclonal antibodies, treatment with carotuximab can lead to a range of side effects. Common side effects include:

More serious side effects may occur and require careful monitoring by healthcare professionals.

Future Directions[edit]

Ongoing research aims to enhance the effectiveness of carotuximab by identifying biomarkers that predict response to treatment and by developing strategies to overcome resistance. The integration of carotuximab into personalized cancer treatment regimens is a key area of interest.

Related Pages[edit]

@@ Line 1: / Line 1: @@
-{{Infobox drug
+{{Short description|A monoclonal antibody used in cancer treatment}}
-| type              = mab
-| image             =
-| alt               =
-| mab_type          =
-| source            = xi/o
-| target            = [[endoglin]]
-| pronounce         =
-| tradename         =
-| Drugs.com         =
-| MedlinePlus       =
-| pregnancy_AU      =
-| pregnancy_US      =
-| pregnancy_category=
-| legal_AU =
-| legal_AU_comment =
-| legal_BR =
-| legal_BR_comment =
-| legal_CA =
-| legal_UK =
-| legal_US =
-| legal_UN =
-| legal_NZ =
-| legal_status      =
-| routes_of_administration =
-| bioavailability   =
-| protein_bound     =
-| metabolism        =
-| metabolites       =
-| onset             =
-| elimination_half-life =
-| duration_of_action=
-| excretion         =
-| CAS_number        = 1268714-50-6
-| ATC_prefix        = none
-| ATC_suffix        =
-| PubChem           =
-| DrugBank          =
-| C = 6420 | H = 9922 | N = 1718 | O = 2010 | S = 46
-| molecular_weight  = 144.8 g/mol
-| UNII = YB2EWE6139
-| KEGG = D11260
-| synonyms = TRC-105
-| ChemSpiderID = none
-}}
-'''Carotuximab''' ([[International Nonproprietary Name|INN]]<ref name=WHOList114>{{cite journal | author = [[World Health Organization]] | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 114 | journal = WHO Drug Information | volume = 29 | issue = 4 | year = 2015 | url = http://www.who.int/medicines/publications/druginformation/innlists/PL114.pdf | format=PDF}}</ref>) ('''TRC-105''') is a chimeric monoclonal antibody designed for the treatment of cancer.
+'''Carotuximab''' is a [[monoclonal antibody]] that has been investigated for its potential use in the treatment of various types of [[cancer]]. It is designed to target specific proteins on the surface of cancer cells, thereby inhibiting their growth and proliferation.
-This drug was developed by Tracon Pharmaceuticals Inc.<ref>[https://searchusan.ama-assn.org/undefined/documentDownload?uri=%2Funstructured%2Fbinary%2Fusan%2Fcarotuximab.pdf Statement On A Nonproprietary Name Adopted By The USAN Council - Carotuximab], [[American Medical Association]].</ref>
+==Mechanism of Action==
+Carotuximab functions by binding to a specific [[antigen]] present on the surface of certain cancer cells. This binding can block the signaling pathways that promote tumor growth and survival. Additionally, carotuximab may recruit components of the [[immune system]] to attack and destroy the cancer cells.
-It is at Phase III trials for [[angiosarcoma]].
+==Clinical Applications==
+Carotuximab has been studied in clinical trials for its efficacy in treating several types of cancer, including:
+* [[Glioblastoma]]
+* [[Melanoma]]
+* [[Renal cell carcinoma]]
+In these studies, carotuximab has been evaluated both as a monotherapy and in combination with other [[chemotherapeutic agents]].
+==Development and Research==
+The development of carotuximab involves extensive [[preclinical]] and [[clinical trials]] to assess its safety, efficacy, and optimal dosing regimens. Research is ongoing to determine the full potential of carotuximab in cancer therapy, including its use in combination with other [[targeted therapies]] and [[immunotherapies]].
+==Side Effects==
+As with many monoclonal antibodies, treatment with carotuximab can lead to a range of side effects. Common side effects include:
+* [[Infusion reactions]]
+* [[Fatigue]]
+* [[Nausea]]
+* [[Rash]]
+More serious side effects may occur and require careful monitoring by healthcare professionals.
+==Future Directions==
+Ongoing research aims to enhance the effectiveness of carotuximab by identifying biomarkers that predict response to treatment and by developing strategies to overcome resistance. The integration of carotuximab into personalized cancer treatment regimens is a key area of interest.
+==Related Pages==
+* [[Monoclonal antibody therapy]]
+* [[Cancer immunotherapy]]
+* [[Targeted therapy]]
-== References ==
-<references/>
-{{Monoclonal-antibody-stub}}
-{{Monoclonals for tumors}}
 [[Category:Monoclonal antibodies]]
-{{dictionary-stub1}}
+[[Category:Cancer treatments]]
-{{No image}}